Pfizer’s Anti-Bribery Policy, a Decade After DOJ/SEC Settlement

Harry Cassin looks at the current anti-bribery policy of pharmaceutical giant Pfizer, which a decade ago paid $60 million to settle bribery allegations in eleven countries across Eurasia. He writes that its prohibition of facilitating payments is similar to the policies of Apple, Novartis, Microsoft, Volkswagen, Airbus, GM, and 3M, and more stringent than Coca-Cola’s […]
Must be a Paid Member or a Free Trial Member to Access Content. Members log in here.